Effect of a Mixture of Fibers and Carbohydrates on Intestinal Transit in Children Diagnosed With Functional Constipation

NCT ID: NCT04028258

Last Updated: 2020-03-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-13

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Once the patients who are candidates to enter the study are identified, the patients will be randomly be assigned to two groups, according to the sequence:

* Group A: study product+wash out+control product
* Group B: control product+wash out+study product

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients will be given guidelines for adopting dietary habits and healthy lifestyles to achieve a regular and physiological depositional rhythm and will be given a study supplement and a control supplement, alternatively, for 2 time periods of 3 weeks separated by 2 weeks of wash out.

* Supplement under study: mixture of food fibers of plant origin, in a proportion that contributes 75% soluble fiber / 25% insoluble fiber.
* Control: Placebo supplement: maltodextrin and plum flakes

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Constipation - Functional

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A: study+wash out+control

Study product (3 weeks) + wash out (2 weeks) + control product (3 weeks)

Group Type OTHER

Mixture of fibers + Placebo

Intervention Type DIETARY_SUPPLEMENT

Study product: mixture of plant-based food fibers (3 weeks) + wash out (2 weeks) + placebo control : plum flakes + maltodextrin (3 weeks)

Group B: control+wash out+study

Control product (3 weeks) + wash out (2 weeks) + study product (3 weeks)

Group Type OTHER

Placebo + Mixture of fibers

Intervention Type DIETARY_SUPPLEMENT

Placebo control: plum flakes + maltodextrin (3 weeks) + wash out (2 weeks) + study product: mixture of plant-based food fibers (3 weeks)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mixture of fibers + Placebo

Study product: mixture of plant-based food fibers (3 weeks) + wash out (2 weeks) + placebo control : plum flakes + maltodextrin (3 weeks)

Intervention Type DIETARY_SUPPLEMENT

Placebo + Mixture of fibers

Placebo control: plum flakes + maltodextrin (3 weeks) + wash out (2 weeks) + study product: mixture of plant-based food fibers (3 weeks)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Boys and girls aged 3 to 12
* Diagnosis of functional constipation according to Rome IV criteria

Exclusion Criteria

* Regular use of a dietary fiber supplement, prebiotics or probiotics in the previous 30 days, or who would have been taking bulk-forming agents or laxatives in the 2 weeks prior to the study
* Use of medications that cause constipation
* Children with organic constipation such as Hirschsprung's disease, cerebral paralysis, anorectal and spinal cord abnormalities and metabolic diseases.
* Patients who are not likely to complete follow-up
Minimum Eligible Age

3 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Laboratorios Ordesa

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gerardo Rodríguez, MD

Role: PRINCIPAL_INVESTIGATOR

Instituto de Investigación Sanitaria Aragón

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centro de Salud Perpetuo Socorro

Huesca, Aragon, Spain

Site Status RECRUITING

Centro de Salud Amparo Poch

Zaragoza, Aragon, Spain

Site Status RECRUITING

Centro de Salud Isabel II

Santander, Cantabria, Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Roser De Castellar, MD

Role: CONTACT

+34 902105243

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jorge Fuertes, MD

Role: primary

974 225 450

Isabel Lostal, MD

Role: primary

976 547 499

Maria Rosa Pardo

Role: primary

942218161

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VEGY-DOWN (A)-05-17

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fibers and Gut Health
NCT02234518 COMPLETED NA
CMTS4520 for Chronic Constipation in Adults
NCT06832137 NOT_YET_RECRUITING PHASE1/PHASE2